How it works, simply
It mimics part of parathyroid hormone; intermittent exposure can stimulate bone formation.
What the evidence tells us
This is a disease-specific treatment, not evidence for general athletic recovery.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
- Hypercalcemia and orthostatic symptoms are relevant concerns.
- The label advises avoiding use in people with certain increased risks of osteosarcoma.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Intermittent PTH1 receptor activation supports bone formation in indicated high-risk populations.
Sponsor or developer: Multiple manufacturers
Studied or labeled topics: Osteoporosis, High fracture risk
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- DailyMed: FORTEO prescribing information ↗ · Regulator · Aug 19, 2026
Product labels and further research
These directories help locate records. They are not individual studies supporting every statement.
Readability updated October 10, 2026. Evidence review: October 10, 2026 (linked label: purpose and selected risks). A wording update is not a new clinical review.